IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter

Sector
Healthcare
Filed
Jul 10, 2026
Apnimed, Inc.
Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.
Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).
Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 10, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 1, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Apr 22, 2026 | [Amend] [Cover] Draft Registration Statement |
| D | Mar 27, 2026 | Notice of Exempt Offering of Securities |
| DRS/A | Feb 17, 2026 | [Amend] [Cover] Draft Registration Statement |
| D/A | Dec 8, 2025 | Filing |
| D/A | Oct 1, 2025 | Filing |
| D | Sep 24, 2025 | Notice of Exempt Offering of Securities |
| D | Apr 24, 2025 | Notice of Exempt Offering of Securities |
| DRS | Jul 1, 2024 | [Cover] Draft Registration Statement |
Contact and headquarters details
Key executives and officers
Kevin R. Lind
Chief Executive Officer and Director
Michael Kelly
Chief Financial Officer
Dennis P. Molnar
President and Chief Operating Officer
John Cronin, M.D.
Chief Medical Officer
Graham Goodrich
Chief Commercial Officer
Barry Wohl
Chief Business Officer
Steven Spector, J.D.
Chief Legal Officer and Head of Corporate Affairs
Paul Sekhri
Director, Board Chair
Lawrence G. Miller, M.D.
Director, Vice Chair
Joseph Avellone, M.D.
Director